The clinical potential of cyclooxygenase-2-specific inhibitors.
Clinical symposium : COX-2-Specific Inhibitors : Basic Science and Clinical Implications. Dallas, TX, USA, 1998/04/01.
Emerging evidence suggests that cyclooxygenase-2 (COX-2) has diverse physiologic and pathophysiologic functions.
It is expressed constitutively in the developing kidney and brain, playing a role in their proper maturation and function.
Further, COX-2 expression may be up-regulated at certain sites :
in the kidney during sodium restriction ;
in the microglia of cognitive centers within the hippocampus and cortex in Alzheimer's disease ;
and in intestinal adenomas and colon tumors.
On the basis of COX-2 expression in Alzheimer's disease and colon cancer, COX-2-specific inhibitors may find clinical utility in the prevention or treatment of these conditions.
Despite this apparently optimistic outlook for future uses of COX-2 inhibitors, most of the findings supporting this perspective are based on in vitro and in vivo models and must be rigorously corroborated in human studies, some of which are already planned.
Mots-clés Pascal : Prostaglandin-endoperoxide synthase, Oxidoreductases, Enzyme, Propriété physicochimique, Pharmacocinétique, Inhibiteur, Spécificité, Protocole expérimental, Application médicale, In vitro, In vivo, Homme, Prostaglandine
Mots-clés Pascal anglais : Prostaglandin-endoperoxide synthase, Oxidoreductases, Enzyme, Physicochemical properties, Pharmacokinetics, Inhibitor, Specificity, Experimental protocol, Medical application, In vitro, In vivo, Human, Prostaglandin
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 99-0346844
Code Inist : 002B02L. Création : 14/12/1999.